Skip to content

Author

Ye-Qian Feng

We have 3 of 16 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Tumor cell membrane‑coated MOF‑199 nanoparticles co‑loaded with auranofin and celecoxib enhance single‑dose radiotherapy and anti‑PD‑L1 therapy in cervical cancer

Cervical cancer (CC) remains one of the leading causes of cancer-related death among women worldwide. Radiotherapy (RT) is an integral component of multimodal treatment for CC. Beyond its direct cytotoxic effects mediated by radiation-induced DNA damage, RT can also elicit antitumor immunity by promoting the generation...

Chen-Zhe Feng, Jun-Jie Wang, Yong-Jing Zhang et al. · 0 citations
Review Open access Sep 2026

Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design

A biomarker-guided strategy that combines tumor visibility, immune-cell state, spatial architecture, systemic inflammation, and early treatment dynamics to identify the dominant resistance topology is proposed to restore productive immune pressure while limiting compensatory escape and toxicity.

Xiao-Dong Wang, Jia-Yi Liu, Alifujiang Hairulajiang et al. · 0 citations
Jul 2026

RBCK1 promotes chemotherapy resistance in bladder carcinoma by targeting HLTF.

Integrated analysis of public transcriptomic datasets identify an RBCK1-HLTF-JAK2/STAT3 regulatory axis that promotes cisplatin resistance in bladder cancer cells, and xenograft validation further supports the role of RBCK1 depletion in enhancing cisplatin response in vivo.

Xin Yang, Ze-Xian Ding, Peng-Wang Ya et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.